Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression

Hepatology

Volumn 29, Issue 4, 1999, Pages 1007-1012

  Degott, Claude ^a   Zafrani, Elie Serge ^b   Callard, Patrice ^c   Balkau, Beverley ^d   Poupon, Renée Eugénie ^d   Poupon, Raoul ^e,f  

^a BEAUJON HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL TENON   (France)

^d INSERM   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILE DUCT DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEPATIC DUCT; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032898075     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290444     Document Type: Article

References (21)

1. Poupon RE, Balkau B, Eschwège E, Poupon R, and the UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-1554.
2. Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994:330:1342-1347.
3. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh P, Harrison JM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.
4. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, et al. The Canadian multicenter double-blind randomized controlled trial of Ursodeoxycholic acid in primary biliary cirrhosis. HEPATOLOGY 1994;19:1149-1156.
5. Combes B, Carithers R, Maddrey WC, Li D, McDonald MF, Wheeler DE, Eidenbdrot EH, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholate in primary biliary cirrhosis. HEPATOLOGY 1995;22:759-766.
6. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of Ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.
7. Lehman EL. In: Nonparametrics. New York: McGraw-Hill International Book Company, 197:233.
8. Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 1985;88:1777-1790.
9. Christensen E, Crowe JP, Doniach D, Popper H, Ranek L. Rodés J, Tygstrup N, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 1980;78:236-246.
10. Popper H. The problem of histologic evaluation of primary biliary cirrhosis. Virchows Arch [Pathol Anat] 1978;379-99-102.
11. Portmann BC, MacSween RNM. Disease of the intrahepatic bile ducts. In: MacSween RNM, Anthony PP, Scheuer PJ, eds. Pathology of the Liver. Edinburgh/London/Melbourne/New York: Churchill Livingstone, 1987:424-453.
12. Desmet VJ. Vanishing bile duct disorders. In: Boyer JL, Ockner R, eds. Progress in Liver Diseases. Philadelphia: Saunders 1992:89-121.
13. Locke GR III, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. HEPATOLOGY 1996;23:52-56.
14. Poupon RE, Chrétien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. HEPATOLOGY 1993;17:599-604.
15. Van Nieuwkerk CMJ, Oude Elferink RPJ, Groen AK, Ottenhoff R, Tytgat GNJ, Dingemans KP, Van den Bergh Weerman MA, et al. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with disrupted mdr2 P-glycOprotein gene. Gastroenterology 1996;111:165-171.
16. Koga H, Sakisaka S, Ohishi M, Sala M, Tanikawa K. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. HEPATOLOGY 1997;25:1077-1084.
17. Saeki R, Ogino H, Kaneko S, Unoura M, Kobayashi K. Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-γ production by peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J Gastroenterol 1995;30:739-744.
18. Tanaka H, Makino Y, Miura T, Hirano F, Okamoto K, Komura K, Sato Y, et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-γ-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 1996;156:1601-1608.
19. Joplin R, Lindsay JG, Johnson GD, Strain A, Neuberger J. Membrane dihydrolipoamide acetyltransferase (E2) on human biliary epithelial cells in primary biliary cirrhosis. Lancet 1992;339:93-94.
20. Leung PSC, Van de Water J, Coppel RL, Nakanuma Y, Munoz S, Gershwin ME. Molecular aspects and the pathological basis of primary biliary cirrhosis. J Autoimmun 1996;9:119-128.
21. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. HEPATOLOGY 1998;28:296-301.